Charles River Laboratories International (CRL) Cash from Financing Activities (2009 - 2026)

Charles River Laboratories International has reported Cash from Financing Activities for 18 years, with the latest figure at -$164.7 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 27.44% year-over-year to -$164.7 million in Q2 2026; TTM through Jun 2026 was -$21.4 million, a 96.52% increase from a year earlier, with the FY2025 full-year figure at -$536.7 million, up 2.58% from the prior year.
• Cash from Financing Activities was -$164.7 million for Q2 2026 at Charles River Laboratories International, down from $347.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $347.7 million in Q1 2026, with the low at -$285.9 million in Q2 2024.
• Average Cash from Financing Activities over 5 years is -$57.4 million, with a median of -$73.7 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities slumped 674.1% in 2025, then soared 430.14% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$249.0 million in 2022, then surged by 149.63% to $123.6 million in 2023, then slumped by 161.41% to -$75.9 million in 2024, then jumped by 31.65% to -$51.9 million in 2025, then plunged by 217.49% to -$164.7 million in 2026.
• The last three Cash from Financing Activities figures came in at -$164.7 million (Q2 2026), $347.7 million (Q1 2026), and -$51.9 million (Q4 2025), per Business Quant data.